

Supplementary Material

Supplementary Table 1. Baseline characteristics of non-hospitalized patients with COVID-19 in (a) outpatient molnupiravir and respective matched control groups, and (b) outpatient nirmatrelvir/ritonavir and respective matched control groups before 1:10 propensity score matching

Supplementary Table 2. Characteristics of case and control groups for outcomes of all-cause mortality, hospitalization, and composite in-hospital outcome after matching

Supplementary Table 3. Subgroup analyses of outcomes for (a) outpatient molnupiravir users versus matched controls, and (b) outpatient nirmatrelvir/ritonavir users versus matched controls by vaccination status and age groups

Supplementary Table 1. Baseline characteristics of non-hospitalized patients with COVID-19 in (a) outpatient molnupiravir and respective matched control groups, and (b) outpatient nirmatrelvir/ritonavir and respective matched control groups before 1:10 propensity score matching

Baseline characteristics	Before 1:10 matching									
	Molnupiravir (n=5,257)		Control (n=918,309)		SMD	Nirmatrelvir/ritonavir (n=5,663)		Control (n=918,309)		SMD
	N / Mean	% / SD	N / Mean	% / SD		N / Mean	% / SD	N / Mean	% / SD	
Age, years †	75.0	12.6	49.2	16.7	1.54	70.4	11.9	49.2	16.7	1.27
18-40	88	(1.7%)	319,988	(34.9%)		135	(2.4%)	319,988	(34.9%)	
40-65	925	(17.6%)	433,792	(47.2%)	1.70	1,594	(28.2%)	433,792	(47.2%)	1.36
>65	4,244	(80.7%)	164,529	(17.9%)		3,934	(69.5%)	164,529	(17.9%)	
Sex					0.03					0.00
Male	2,501	(47.6%)	423,790	(46.1%)		2,609	(46.1%)	423,790	(46.1%)	
Female	2,756	(52.4%)	494,519	(53.9%)		3,054	(53.9%)	494,519	(53.9%)	
Pre-existing comorbidities										
Charlson's Index †	3.9	1.3	1.7	1.5	1.42	3.4	1.1	1.7	1.5	1.11
0-4	4,517	(85.9%)	912,655	(99.4%)		5,373	(94.9%)	912,655	(99.4%)	
5-6	498	(9.5%)	3,724	(0.4%)	0.53	243	(4.3%)	3,724	(0.4%)	0.27
7-14	242	(4.6%)	1,930	(0.2%)		47	(0.8%)	1,930	(0.2%)	
Fully vaccinated*	859	(16.3%)	501,302	(54.6%)	0.87	1,992	(35.2%)	501,302	(54.6%)	0.40

Notes: SD = standard deviation; SMD = standardized mean difference

* Fully vaccinated patients were defined as those with at least 2 doses of Comirnaty or 3 doses of CoronaVac.

† Age and Charlson Comorbidity Index are presented in mean ± SD.

Supplementary Table 2. Characteristics of case and control groups for outcomes of all-cause mortality, hospitalization, and composite in-hospital outcome after matching

Characteristics	All-cause mortality				Hospitalization				Composite in-hospital outcome			
	Case (n=1,084)		Control (n=10,454)		Case (n=2,052)		Control (n=19,099)		Case (n=880)		Control (n=8,438)	
	N / Mean	% / SD	N / Mean	% / SD	N / Mean	% / SD	N / Mean	% / SD	N / Mean	% / SD	N / Mean	% / SD
Age, years †	80.0	13.5	80.7	11.4	55.1	20.3	54.6	17.7	74.5	15.7	74.9	14.2
18-40	18	(1.7%)	90	(0.9%)	654	(31.9%)	4,653	(24.4%)	37	(4.2%)	204	(2.4%)
40-65	137	(12.6%)	855	(8.2%)	695	(33.9%)	8,752	(45.8%)	190	(21.6%)	1,755	(20.8%)
>65	929	(85.7%)	9,509	(91.0%)	703	(34.3%)	5,694	(29.8%)	653	(74.2%)	6,479	(76.8%)
Sex												
Male	643	(59.3%)	6,128	(58.6%)	908	(44.2%)	8,504	(44.5%)	515	(58.5%)	4,813	(57.0%)
Female	441	(40.7%)	4,326	(41.4%)	1,144	(55.8%)	10,595	(55.5%)	365	(41.5%)	3,625	(43.0%)
Pre-existing comorbidities												
Charlson's Index †‡	5.1	2.0	4.9	1.8	2.3	2.1	2.2	1.6	5.5	2.1	5.1	2.1
1-4	540	(49.8%)	6,039	(57.8%)	1,738	(84.7%)	18,189	(95.2%)	264	(30.0%)	3,419	(40.5%)
5-6	312	(28.8%)	2,567	(24.6%)	265	(12.9%)	838	(4.4%)	377	(42.8%)	3,089	(36.6%)
7-14	232	(21.4%)	1,848	(17.7%)	49	(2.4%)	72	(0.4%)	239	(27.2%)	1,930	(22.9%)
Full SARS-CoV-2 vaccination	235	(21.7%)	2,047	(19.6%)	813	(39.6%)	8,458	(44.3%)	292	(33.2%)	2,886	(34.2%)

Notes: SD = standard deviation; SMD = standardized mean difference

* Fully vaccinated patients were defined as those with at least 2 doses of Comirnaty or 3 doses of CoronaVac.

† Age and Charlson Comorbidity Index are presented in mean ± SD.

Supplementary Table 3. Subgroup analyses of outcomes for (a) outpatient molnupiravir users versus matched controls, and (b) outpatient nirmatrelvir/ritonavir users versus matched controls by vaccination status and age groups

Outcomes	Molnupiravir (N=4,875)			Control (N=48,409)			Molnupiravir vs Control			
	Crude incidence rate (Events / 100,000 person-days)			Crude incidence rate (Events / 100,000 person-days)						
	Estimate	95% CI	Person-days	Estimate	95% CI	Person-days	HR†	95% CI	P-value	P _{int}
All-cause mortality	24.2	(17.8, 32.1)	198,397	38.0	(35.3, 40.7)	2,033,869	0.61	(0.46, 0.82)	<0.001	
With full SARS-CoV-2 vaccination	3.4	(0.1, 18.7)	29,724	9.1	(5.7, 13.6)	253,726	NA	NA	NA	NA
Without full SARS-CoV-2 vaccination	27.9	(20.5, 37.1)	168,673	42.1	(39.1, 45.2)	1,780,143	0.63	(0.47, 0.85)	0.002	
Age ≤65	5.1	(0.6, 18.2)	39,601	6.5	(4.2, 9.7)	369,650	0.77	(0.18, 3.30)	0.726	0.730
Age >65	29.0	(21.2, 38.6)	158,796	44.9	(41.8, 48.3)	1,664,219	0.61	(0.45, 0.82)	0.001	
Hospitalization	296.0	(271.4, 322.3)	179,704	269.2	(261.7, 276.8)	1,844,538	1.06	(0.97, 1.16)	0.191	
With full SARS-CoV-2 vaccination	115.1	(79.2, 161.6)	28,680	184.7	(167.9, 202.7)	239,306	0.62	(0.44, 0.89)	0.009	0.003
Without full SARS-CoV-2 vaccination	330.4	(302.1, 360.7)	151,024	281.8	(273.6, 290.1)	1,605,232	1.12	(1.02, 1.23)	0.013	
Age ≤65	258.1	(208.6, 315.9)	36,418	168.9	(155.6, 183.1)	348,653	1.59	(1.28, 1.99)	<0.001	<0.001
Age >65	305.7	(277.7, 335.7)	143,286	292.5	(283.9, 301.3)	1,495,885	0.99	(0.89, 1.09)	0.782	
In-hospital disease progression	31.9	(24.5, 40.8)	197,791	47.7	(44.7, 50.8)	2,024,497	0.64	(0.50, 0.83)	<0.001	
With full SARS-CoV-2 vaccination	13.5	(3.7, 34.6)	29,598	18.6	(13.7, 24.7)	252,829	0.74	(0.26, 2.05)	0.557	0.845
Without full SARS-CoV-2 vaccination	35.1	(26.7, 45.2)	168,193	51.8	(48.5, 55.3)	1,771,668	0.65	(0.50, 0.84)	0.001	
Age ≤65	20.3	(8.8, 40.0)	39,392	17.7	(13.6, 22.5)	368,061	1.17	(0.56, 2.44)	0.676	0.092
Age >65	34.7	(26.2, 45.2)	158,399	54.3	(50.8, 58.0)	1,656,436	0.60	(0.46, 0.79)	<0.001	
In-hospital death	23.2	(17.0, 30.9)	198,397	37.9	(35.2, 40.6)	2,033,869	0.59	(0.44, 0.79)	<0.001	
With full SARS-CoV-2 vaccination	3.4	(0.1, 18.7)	29,724	9.1	(5.7, 13.6)	253,726	NA	NA	NA	NA
Without full SARS-CoV-2 vaccination	26.7	(19.5, 35.7)	168,673	42.0	(39.0, 45.1)	1,780,143	0.61	(0.45, 0.82)	0.001	
Age ≤65	2.5	(0.1, 14.1)	39,601	6.5	(4.2, 9.7)	369,650	NA	NA	NA	NA
Age >65	28.3	(20.7, 37.9)	158,796	44.8	(41.7, 48.2)	1,664,219	0.60	(0.44, 0.81)	<0.001	
Invasive mechanical ventilation	4.0	(1.7, 8.0)	198,157	8.7	(7.4, 10.0)	2,030,226	0.45	(0.22, 0.91)	0.027	
With full SARS-CoV-2 vaccination	0.0	NA	29,724	4.7	(2.4, 8.3)	253,415	NA	NA	NA	NA

Without full SARS-CoV-2 vaccination	4.7	(2.1, 9.4)	168,433	9.2	(7.9, 10.8)	1,776,811	0.50	(0.24, 1.01)	0.053	
Age ≤65	7.6	(1.6, 22.2)	39,528	6.0	(3.7, 9.0)	368,913	1.26	(0.38, 4.18)	0.706	0.067
Age >65	3.2	(1.0, 7.4)	158,629	9.3	(7.9, 10.9)	1,661,313	0.32	(0.13, 0.79)	0.013	
Intensive care unit admission	9.1	(5.4, 14.4)	197,829	11.7	(10.2, 13.2)	2,025,071	0.75	(0.46, 1.21)	0.234	
With full SARS-CoV-2 vaccination	10.1	(2.1, 29.6)	29,598	9.5	(6.1, 14.1)	252,833	1.04	(0.31, 3.50)	0.944	0.535
Without full SARS-CoV-2 vaccination	8.9	(5.0, 14.7)	168,231	12.0	(10.4, 13.7)	1,772,238	0.71	(0.42, 1.20)	0.203	
Age ≤65	17.8	(7.1, 36.6)	39,392	11.1	(8.0, 15.1)	368,103	1.65	(0.74, 3.68)	0.221	0.031
Age >65	6.9	(3.5, 12.4)	158,437	11.8	(10.2, 13.5)	1,656,968	0.55	(0.30, 1.01)	0.055	

Outcomes	Nirmatrelvir/ritonavir (N=5,366)			Control (N=53,289)			Nirmatrelvir/ritonavir vs Control			
	Crude incidence rate (Events / 100,000 person-days)			Crude incidence rate (Events / 100,000 person-days)						
	Estimate	95% CI	Person-days	Estimate	95% CI	Person-days	HR†	95% CI	P-value	P _{int}
All-cause mortality	5.2	(2.5, 9.6)	192,552	20.1	(18.1, 22.1)	1,969,245	0.25	(0.13, 0.47)	<0.001	
With full SARS-CoV-2 vaccination	0.0	NA	62,573	3.3	(2.0, 5.0)	611,867	NA	NA	NA	NA
Without full SARS-CoV-2 vaccination	7.7	(3.7, 14.1)	129,979	27.6	(24.9, 30.6)	1,357,378	0.27	(0.14, 0.50)	<0.001	
Age ≤65	0.0	NA	58,491	2.6	(1.4, 4.3)	548,884	NA	NA	NA	NA
Age >65	7.5	(3.6, 13.7)	134,061	26.8	(24.2, 29.7)	1,420,361	0.26	(0.14, 0.49)	<0.001	
Hospitalization	126.2	(110.6, 143.5)	185,406	178.8	(172.7, 184.9)	1,850,613	0.69	(0.60, 0.79)	<0.001	
With full SARS-CoV-2 vaccination	61.6	(43.6, 84.5)	61,696	92.0	(84.4, 100.0)	594,672	0.65	(0.47, 0.91)	0.012	0.838
Without full SARS-CoV-2 vaccination	158.4	(137.0, 182.2)	123,710	219.8	(211.7, 228.2)	1,255,941	0.70	(0.60, 0.81)	<0.001	
Age ≤65	60.8	(42.4, 84.6)	57,525	115.4	(106.5, 125.0)	529,321	0.56	(0.40, 0.79)	<0.001	0.314
Age >65	155.6	(134.7, 178.8)	127,881	204.1	(196.5, 212.0)	1,321,292	0.70	(0.61, 0.81)	<0.001	
In-hospital disease progression	12.5	(8.0, 18.6)	192,078	25.8	(23.6, 28.2)	1,964,548	0.47	(0.31, 0.71)	<0.001	
With full SARS-CoV-2 vaccination	3.2	(0.4, 11.6)	62,505	7.7	(5.7, 10.2)	610,946	0.42	(0.10, 1.73)	0.230	0.835
Without full SARS-CoV-2 vaccination	17.0	(10.6, 25.7)	129,573	34.0	(30.9, 37.2)	1,353,602	0.48	(0.31, 0.73)	<0.001	
Age ≤65	3.4	(0.4, 12.4)	58,436	8.4	(6.1, 11.2)	547,824	0.42	(0.10, 1.75)	0.236	0.916
Age >65	16.5	(10.3, 24.9)	133,642	32.5	(29.6, 35.7)	1,416,724	0.47	(0.31, 0.72)	<0.001	
In-hospital death	4.7	(2.1, 8.9)	192,552	20.0	(18.1, 22.1)	1,969,245	0.23	(0.12, 0.44)	<0.001	

With full SARS-CoV-2 vaccination	0.0	NA	62,573	3.3	(2.0, 5.0)	611,867	NA	NA	NA	NA
Without full SARS-CoV-2 vaccination	6.9	(3.2, 13.1)	129,979	27.6	(24.8, 30.5)	1,357,378	0.24	(0.12, 0.47)	<0.001	NA
Age ≤65	0.0	NA	58,491	2.6	(1.4, 4.3)	548,884	NA	NA	NA	NA
Age >65	6.7	(3.1, 12.7)	134,061	26.8	(24.1, 29.6)	1,420,361	0.23	(0.12, 0.45)	<0.001	NA
Invasive mechanical ventilation	2.1	(0.6, 5.3)	192,412	4.2	(3.3, 5.2)	1,967,711	0.48	(0.18, 1.31)	0.151	
With full SARS-CoV-2 vaccination	1.6	(0.0, 8.9)	62,539	1.6	(0.8, 3.0)	611,683	NA	NA	NA	NA
Without full SARS-CoV-2 vaccination	2.3	(0.5, 6.8)	129,873	5.3	(4.2, 6.7)	1,356,028	0.41	(0.13, 1.31)	0.133	NA
Age ≤65	0.0	NA	58,491	2.4	(1.3, 4.1)	548,584	NA	NA	NA	NA
Age >65	3.0	(0.8, 7.6)	133,921	4.9	(3.8, 6.2)	1,419,127	0.57	(0.21, 1.55)	0.269	NA
Intensive care unit admission	8.3	(4.8, 13.5)	192,099	6.6	(5.5, 7.8)	1,964,733	1.22	(0.73, 2.05)	0.450	
With full SARS-CoV-2 vaccination	3.2	(0.4, 11.6)	62,505	4.4	(2.9, 6.4)	610,965	0.69	(0.16, 2.93)	0.617	0.414
Without full SARS-CoV-2 vaccination	10.8	(5.9, 18.1)	129,594	7.5	(6.1, 9.1)	1,353,768	1.37	(0.78, 2.39)	0.271	
Age ≤65	3.4	(0.4, 12.4)	58,436	5.3	(3.5, 7.6)	547,876	0.70	(0.17, 2.92)	0.621	0.401
Age >65	10.5	(5.7, 17.6)	133,663	7.1	(5.7, 8.6)	1,416,857	1.35	(0.77, 2.35)	0.298	

Notes: HR = hazard ratio; CI = confidence interval; NA = not applicable; P_{int} = P-value for interaction

† HR >1 (or <1) indicates oral antiviral users had higher (lower) risk of outcome compared to the matched control group.

HR were estimated only when the number of events in both groups were more than or equal to 2.